Other substances

S-Trimer

An experimental COVID-19 protein subunit vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

S-Trimer is a candidate COVID-19 subunit vaccine based on a native-like prefusion SARS-CoV-2 Spike protein trimer produced using Trimer-Tag technology. The vaccine is adjuvanted with either AS03 (oil emulsion in water) or CpG 1018 (TLR9 agonist)/alum. Its efficacy has been manifested in animal model experiments (Liang et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates Spike protein Protein factor Animal model Mixed substance	in vitro binding assay; in vitro biophysical assay; electron microscopy; BALB/c mice; Sprague Dawley rats; rhesus macaques; SARS-CoV-2 pseudovirus; SARS-CoV-2 strain 107	12.12	The candidate vaccine (adjuvanted) elicited potent neutralizing antibody and Th1-biased T cell responses in mice, rats, and rhesus macaques. Adjuvanted immunization led to viral load reduction in rhesus macaques in a viral challenge study. The primates were also protected from the SARS-CoV-2 infection based on clinical observations and reduced lung pathology.	Mar/01/2021

AI-suggested references

Link	Publication date
MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern	Feb/02/2022
Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19	Mar/10/2021
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity	Jan/24/2022
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines	Jun/30/2021
Insight into Vaccine Development for Alphacoronaviruses Based on Structural and Immunological Analyses of Spike Proteins	Oct/18/2021
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	Jul/13/2021
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines	Nov/12/2021
Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine	May/30/2020
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain	Aug/05/2021
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.	Sep/27/2021

Export (.csv)